Alcobra Ltd. - Ordinary Shares shares had a trading volume of 6,572 in the last trading session.
According to Zacks, "Alcobra Ltd.is a biopharmaceutical company". It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Alcobra Ltd.is headquartered in Tel Aviv, Israel.
A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Alcobra from a hold rating to a buy rating and set a $1.25 price target for the company in a research note on Tuesday, July 18th. Roth Capital cut Alcobra from a buy rating to a neutral rating and decreased their target price for the stock from $4.00 to $1.00 in a report on Friday, September 29th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. Alcobra has a consensus rating of Hold and an average target price of $1.56. This recommendation lands on a scale between 1 and 5. The company's stock had a trading volume of 4,065,860 shares. The company's market cap is $31.70 million. Looking at a shorter time period, shares have been seen -8.48% away from the 50 day high and 120.28% off the 50 day low price.
Principal and team removed from school for "concealing" sexual abuse of pupils
He said removing them from the school was to make sure that they do not have contact with the pupils while the investigation is ongoing.
Several analysts have released their opinion on Alcobra Ltd. (NASDAQ:ADHD), with 0 analysts believing it is a strong buy.
In the latest earnings report the EPS was $-0.76 and is expected to be $-0.50 for the current year with 27,562,000 shares outstanding. Next quarter's EPS is forecasted to be $-0.07 with next year's EPS anticipated to be $-0.53.
COPYRIGHT VIOLATION WARNING: "Alcobra Ltd. (ADHD) Upgraded at WBB Securities" was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another website, it was stolen and reposted in violation of US & worldwide trademark & copyright legislation.
Medidata Solutions Inc (MDSO) Draws Bullish Attention After Forming Double Top
After $1.06 actual EPS reported by Welltower Inc for the previous quarter, Wall Street now forecasts -0.94% negative EPS growth. The stock has "Buy" rating by Needham on Friday, February 10. (NASDAQ:CSCO) earned "Buy" rating by UBS on Thursday, August 18.
These firms have modified their investment in ADHD.
An institutional investor recently raised its position in Alcobra stock. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company's stock valued at $114,000 after acquiring an additional 101,514 shares during the period. Royce & Associates LP now owns 745,055 shares of the biotechnology company's stock worth $849,000 after purchasing an additional 100,000 shares during the period. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Susan Collins says she won't run for ME governor in 2018
The pull of legacy and a chance to take the reins of state government were not enough to convince Republican U.S. Collins said previously that she'd like to heal the state and "bring people back together".